Bristol Myers Squibb appointed Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer. She succeeds Sandra Leung, who is retiring after 33 years with the company.
Gallman, who has been with Bristol Myers Squibb for a decade, most recently served as Executive Vice President of Corporate Affairs. Gallman will now oversee the company’s law department along with global and U.S. policy and government affairs. Her responsibilities span areas including intellectual property, commercial and regulatory law, litigation, securities and corporate governance, transactions, corporate security and compliance and ethics. Additionally, she was responsible for advancing the company’s strategy through strategic communication, government relations and policy, corporate responsibility, corporate marketing and brand reputation and patient advocacy.
“Cari brings a unique combination of legal, policy and communications expertise, coupled with an impressive ability to inspire teams, uphold ethical business practices and champion patient voices,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. “I am confident that under Cari’s leadership, our legal and policy teams are well-positioned to advance Bristol Myers Squibb’s efforts to drive and deliver innovation to patients facing serious diseases.”
On Sandra Leung’s retirement, Boerner added, “Sandy’s resilience, steadfast leadership, and unwavering commitment to patients have left an indelible mark on our company. On behalf of the entire organization, I want to express our deepest gratitude to Sandy for her decades of service and wish her all the best in her well-deserved retirement.”
Previously, Gallman served as Chief Compliance and Ethics Officer, where she focused on upholding the company’s commitment to ethical business practices and regulatory compliance in the global markets in which it operates. Since joining Bristol Myers Squibb in 2015, she has taken on several leadership roles, including leading the legal team for the Global Oncology Commercialization and Development organizations.
“It is an honor to have the opportunity to lead the incredible teams that govern and counsel Bristol Myers Squibb in advancing its mission to deliver transformational medicines to more patients,” said Gallman. “I am committed to continuing to build on the company’s culture of integrity and shape a dynamic policy environment that protects innovation and patients.”
Gullman began her legal career in private practice representing pharmaceutical and medical device manufacturers in a variety of complex civil, regulatory and government enforcement matters. She earned a bachelor’s degree in political theory from Princeton University and a JD from Harvard Law School.